Single Ascending Dose Tolerability Study of DG3173

Phase 1 Completed 72 enrolled Aspireo Pharmaceuticals Limited DeveloGen AG, Germany · collab

RandomizedSingle-groupQuadruple-blindTreatment

Summary

This clinical trial investigated the safety, tolerability and pharmacokinetic profile of DG3173 in a double-blind, randomized, placebo-controlled, single dose escalation Phase 1 study involving 72 healthy volunteers. Individuals received up to 2000 µg of DG3173 via single dose subcutaneous injection.

Timeline

Start: 2008-05
Primary completion: 2008-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	veldoreotide	Protein / enzyme biologic	2000 ug	Subcutaneous

Indications

No indication recorded.